417 related articles for article (PubMed ID: 27350621)
1. Switching from immediate- to extended-release cysteamine in nephropathic cystinosis patients: a retrospective real-life single-center study.
Ahlenstiel-Grunow T; Kanzelmeyer NK; Froede K; Kreuzer M; Drube J; Lerch C; Pape L
Pediatr Nephrol; 2017 Jan; 32(1):91-97. PubMed ID: 27350621
[TBL] [Abstract][Full Text] [Related]
2. The effects of transitioning from immediate release to extended release cysteamine therapy in Norwegian patients with nephropathic cystinosis: a retrospective study.
Bjerre A; Aase SA; Radtke M; Siva C; Gudmundsdottir H; Forsberg B; Woldseth B; Brackman D
Pediatr Nephrol; 2023 Nov; 38(11):3671-3679. PubMed ID: 37219641
[TBL] [Abstract][Full Text] [Related]
3. Cystinosis: renal glomerular and renal tubular function in relation to compliance with cystine-depleting therapy.
Nesterova G; Williams C; Bernardini I; Gahl WA
Pediatr Nephrol; 2015 Jun; 30(6):945-51. PubMed ID: 25526929
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients.
Bouazza N; Tréluyer JM; Ottolenghi C; Urien S; Deschenes G; Ricquier D; Niaudet P; Chadefaux-Vekemans B
Orphanet J Rare Dis; 2011 Dec; 6():86. PubMed ID: 22195601
[TBL] [Abstract][Full Text] [Related]
5. A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis.
van Stein C; Klank S; Grüneberg M; Ottolenghi C; Grebe J; Reunert J; Harms E; Marquardt T
Orphanet J Rare Dis; 2021 Sep; 16(1):387. PubMed ID: 34521447
[TBL] [Abstract][Full Text] [Related]
6. A randomized controlled crossover trial with delayed-release cysteamine bitartrate in nephropathic cystinosis: effectiveness on white blood cell cystine levels and comparison of safety.
Langman CB; Greenbaum LA; Sarwal M; Grimm P; Niaudet P; Deschênes G; Cornelissen E; Morin D; Cochat P; Matossian D; Gaillard S; Bagger MJ; Rioux P
Clin J Am Soc Nephrol; 2012 Jul; 7(7):1112-20. PubMed ID: 22554716
[TBL] [Abstract][Full Text] [Related]
7. [Cystinosis : Diagnosis, cystine-depleting therapy, and transition].
Kaufeld J; Weber LT; Kurschat C; Canaan-Kuehl S; Brand E; Oh J; Pape L
Internist (Berl); 2018 Aug; 59(8):861-867. PubMed ID: 29671012
[TBL] [Abstract][Full Text] [Related]
8. Long-term treatment of cystinosis in children with twice-daily cysteamine.
Dohil R; Gangoiti JA; Cabrera BL; Fidler M; Schneider JA; Barshop BA
J Pediatr; 2010 May; 156(5):823-7. PubMed ID: 20138296
[TBL] [Abstract][Full Text] [Related]
9. Effects of long-term cysteamine treatment in patients with cystinosis.
Ariceta G; Giordano V; Santos F
Pediatr Nephrol; 2019 Apr; 34(4):571-578. PubMed ID: 29260317
[TBL] [Abstract][Full Text] [Related]
10. Intravenous cysteamine therapy for nephropathic cystinosis.
Gahl WA; Ingelfinger J; Mohan P; Bernardini I; Hyman PE; Tangerman A
Pediatr Res; 1995 Oct; 38(4):579-84. PubMed ID: 8559613
[TBL] [Abstract][Full Text] [Related]
11. Plasma chitotriosidase enzyme activity as a novel therapeutic monitor for cysteamine treatment in nephropathic cystinosis: A retrospective validation study.
Veys K; Elmonem MA; van den Heuvel L; Gahl WA; Levtchenko E
Mol Genet Metab; 2024 May; 142(1):108454. PubMed ID: 38603816
[TBL] [Abstract][Full Text] [Related]
12. Quality of life is improved and kidney function preserved in patients with nephropathic cystinosis treated for 2 years with delayed-release cysteamine bitartrate.
Langman CB; Greenbaum LA; Grimm P; Sarwal M; Niaudet P; Deschenes G; Cornelissen EA; Morin D; Cochat P; Elenberg E; Hanna C; Gaillard S; Bagger MJ; Rioux P
J Pediatr; 2014 Sep; 165(3):528-33.e1. PubMed ID: 24948347
[TBL] [Abstract][Full Text] [Related]
13. Cysteamine therapy for children with nephropathic cystinosis.
Gahl WA; Reed GF; Thoene JG; Schulman JD; Rizzo WB; Jonas AJ; Denman DW; Schlesselman JJ; Corden BJ; Schneider JA
N Engl J Med; 1987 Apr; 316(16):971-7. PubMed ID: 3550461
[TBL] [Abstract][Full Text] [Related]
14. Twice-daily cysteamine bitartrate therapy for children with cystinosis.
Dohil R; Fidler M; Gangoiti JA; Kaskel F; Schneider JA; Barshop BA
J Pediatr; 2010 Jan; 156(1):71-75.e1-3. PubMed ID: 19775699
[TBL] [Abstract][Full Text] [Related]
15. Treatment of cystinosis with delayed-release cysteamine: 6-year follow-up.
Dohil R; Cabrera BL
Pediatr Nephrol; 2013 Mar; 28(3):507-10. PubMed ID: 23001048
[TBL] [Abstract][Full Text] [Related]
16. A comparison of the effectiveness of cysteamine and phosphocysteamine in elevating plasma cysteamine concentration and decreasing leukocyte free cystine in nephropathic cystinosis.
Smolin LA; Clark KF; Thoene JG; Gahl WA; Schneider JA
Pediatr Res; 1988 Jun; 23(6):616-20. PubMed ID: 3393396
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological treatment of nephropathic cystinosis with cysteamine.
Kleta R; Gahl WA
Expert Opin Pharmacother; 2004 Nov; 5(11):2255-62. PubMed ID: 15500372
[TBL] [Abstract][Full Text] [Related]
18. Controversies and research agenda in nephropathic cystinosis: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.
Langman CB; Barshop BA; Deschênes G; Emma F; Goodyer P; Lipkin G; Midgley JP; Ottolenghi C; Servais A; Soliman NA; Thoene JG; Levtchenko EN;
Kidney Int; 2016 Jun; 89(6):1192-203. PubMed ID: 27181776
[TBL] [Abstract][Full Text] [Related]
19. Halitosis in cystinosis patients after administration of immediate-release cysteamine bitartrate compared to delayed-release cysteamine bitartrate.
Besouw M; Tangerman A; Cornelissen E; Rioux P; Levtchenko E
Mol Genet Metab; 2012 Sep; 107(1-2):234-6. PubMed ID: 22832073
[TBL] [Abstract][Full Text] [Related]
20. [Intra-leukocyte cystine in cystinosis treated with cysteamine].
Ged C; Jean G; Tete MJ; Broyer M; Kamoun P
Ann Biol Clin (Paris); 1991; 49(9):482-6. PubMed ID: 1789502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
